- New Litagion agent profile for the industrial gas ethylene oxide
- New liability catastrophe scenarios addressing PFAS-related building contamination
- Updated SARS-CoV-2 litigation tracking data covering 217 complaints filed in U.S. courts
- Updated Litagion agent and company profiles impacted by newly published peer-reviewed science and newly gathered company information
- PFAS-related building contamination. There is growing scientific consensus that exposure to per- and polyfluoroalkyl substances (PFAS), a class of chemicals used to impart water and stain resistance to textiles, food packaging, and other products, has the potential to disrupt the normal functioning of the human endocrine system. Endocrine disruption in turn can lead to a range of chronic disease conditions, including infertility. One of the major applications of PFAS is in carpet. Carpet offgases and degrades over time exposing individuals to PFAS in household dust and indoor air. In these liability catastrophe scenarios, residential building owners file suit alleging that the presence of these materials elevate the risk that occupants will suffer infertility to unacceptable levels and demand compensation for the costs of removing these materials and replacing them with safer alternatives.
- Ethylene oxide. Ethylene oxide [Cas No. 75-21-8] is a highly flammable and reactive gas used as an intermediate in the production of industrial chemicals like ethylene glycol and ethanolamines, which are in turn used to manufacture polyester fibers, fiberglass, household and industrial cleaners, and personal care items including cosmetics and shampoos. Ethylene oxide is also used as a sterilizing agent for heat-sensitive medical devices like plastic syringes and wound-dressings. The Food and Drug Administration estimates that about 50 percent of all sterile medical devices are sterilized using ethylene oxide.
Updated Litagion agent profiles based upon newly published science
All Litagion agent profiles have been updated to reflect the most recently published peer-reviewed science. Notable scientific studies added to CoMeta since the last release include:
- Addictive software design. A study published in March found young males addicted to video gaming had decreased brain gray matter volume when compared to controls.
- Perfluorododecanoic acid (PFDoA). Blood levels of PFDoA were linked to polycystic ovarian syndrome (PCOS) which was determined to be the underlying cause of infertility in a Chinese study.
In addition, we highlight the following changes to the components of Litagion agent risk resulting from newly published peer-reviewed science:
|Litagion agent||Risk category change||Overall risk change|
|Maneb||Projected science risk changes from Low (green) to Medium-low (light green)||No change|
Zinc oxide nanoparticles (Nano-ZnO)
|Projected science risk changes from Medium (yellow) to Medium-high (orange)||Change from Medium (yellow) to Medium-high (orange)|
Old company underwrite mode deprecated
We introduced CoMeta's newly designed company underwriting feature in March of this year. As of this release, the previous version of this feature that was accessed via the projected loss section of the company profile page is no longer available. Users can now navigate to the new company underwriting feature from the left hand navigation bar (1) or by clicking on the blue Underwrite button on a company profile page (2).